Abstract
Innate and adaptive immunity are both involved in prostate cancer (PCa) carcinogenesis and progression. On this scenario, several immunotherapeutic approaches have been proposed and are presently under extensive investigation in PCa patients. Among emerging immune targets, immune checkpoint inhibitors such as anti-cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), anti-Programmed death-1 (PD-1) and anti-Programmed death-ligand-1 (PD-L1) agents seem to represent the most promising candidate for these patients, together with oncolytic viruses and vaccines, used alone or in combined strategies. In this review, we focused on emerging immunotherapeutic approaches in patients with PCa, showing the rational for their association with current standard therapies including anti-androgen agents, chemo- or radiation therapy.
Keywords: Immunotherapy, programmed death-1, prognosis, prostate cancer, vaccines.
Current Drug Targets
Title:Emerging Immunotargets and Immunotherapies in Prostate Cancer
Volume: 17 Issue: 7
Author(s): Rodolfo Montironi, Matteo Santoni, Valeria Sotte, Liang Cheng, Antonio Lopez-Beltran, Francesco Massari, Marc R. Matrana, Holger Moch, Rossana Berardi and Marina Scarpelli
Affiliation:
Keywords: Immunotherapy, programmed death-1, prognosis, prostate cancer, vaccines.
Abstract: Innate and adaptive immunity are both involved in prostate cancer (PCa) carcinogenesis and progression. On this scenario, several immunotherapeutic approaches have been proposed and are presently under extensive investigation in PCa patients. Among emerging immune targets, immune checkpoint inhibitors such as anti-cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), anti-Programmed death-1 (PD-1) and anti-Programmed death-ligand-1 (PD-L1) agents seem to represent the most promising candidate for these patients, together with oncolytic viruses and vaccines, used alone or in combined strategies. In this review, we focused on emerging immunotherapeutic approaches in patients with PCa, showing the rational for their association with current standard therapies including anti-androgen agents, chemo- or radiation therapy.
Export Options
About this article
Cite this article as:
Montironi Rodolfo, Santoni Matteo, Sotte Valeria, Cheng Liang, Lopez-Beltran Antonio, Massari Francesco, R. Matrana Marc, Moch Holger, Berardi Rossana and Scarpelli Marina, Emerging Immunotargets and Immunotherapies in Prostate Cancer, Current Drug Targets 2016; 17 (7) . https://dx.doi.org/10.2174/1389450117666160217123304
DOI https://dx.doi.org/10.2174/1389450117666160217123304 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oncogenic Signalling Networks and Polypharmacology as Paradigms to Cope with Cancer Heterogeneity
Current Proteomics Important Role of Relaxation Techniques in Immune Functions, Glycemic Control, and Stress in Diabetic Patients with COVID-19: A Review
Current Diabetes Reviews Targeting Bcl-2 Family of Proteins: An Important Strategy in Cancer Therapeutics
Current Chemical Biology Anti-Gene Strategies to Down-Regulate Gene Expression in Mammalian Cells
Current Pharmaceutical Design Immune Endocrinological Evaluation in Patients with Severe Vascular Acquired Brain Injuries: Therapeutical Approaches
Endocrine, Metabolic & Immune Disorders - Drug Targets Backbone-Cyclized Peptides: A Critical Review
Current Topics in Medicinal Chemistry Context-dependent Action of Transforming Growth Factor β Family Members on Normal and Cancer Stem Cells
Current Pharmaceutical Design Characterization of Carbonic Anhydrase Isozyme Specific Inhibition by Sulfamated 2-Ethylestra Compounds
Letters in Drug Design & Discovery The Interplay Between Inflammation and Oxidative Stress in Carcinogenesis
Current Molecular Medicine Synthesis and In Vitro Study of the Anticancer Activity of New Analogs of Octreotide
Protein & Peptide Letters Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma
Current Radiopharmaceuticals Current State of the Art for Survival Prediction in Cancer Using Data Mining Techniques
Current Bioinformatics Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy
Current Drug Targets Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry The Role of TNFSF15 in the Modulation of Neovascularization and Inflammation
Current Hypertension Reviews Selectively Replicating Adenoviruses for Oncolytic Therapy
Current Cancer Drug Targets Comprehensive Quality Management (CQM) in the PLCO Trial
Reviews on Recent Clinical Trials Caveolae and Caveolin-1: Novel Potential Targets for the Treatment of Cardiovascular Disease
Current Pharmaceutical Design Recent Progress in Synthesis and Applications of Fluorinated Carbohydrates
Current Organic Chemistry Multidisciplinary Cancer Therapy with Telomerase-Specific Oncolytic Adenovirus
Current Cancer Therapy Reviews